

Supplementary Material

CLINICAL DATA DESCRIPTION

In this study, we enrolled the clinical data from 57 CHF patients. All patients were on optimal drug treatment and underwent CRT device implantation at Almazov National Medical Research Centre between August 2016 and August 2019. Participants signed approved informed form. The study protocol was approved by the Institutional Ethical Committee.

The criteria for patient inclusion in the study were:

- 1. age over 18;
- 2. functional class (FC) II-IV of CHF according to the classification of the New York Heart Association (NYHA) at the outpatient stage of treatment;
- 3. LV EF \leq 35% (Simpson);
- 4. QRS duration (QRSd) more than 120 ms;
- 5. sinus rhythm, left bundle branch block (LBBB);
- 6. optimal drug therapy.

The exclusion criteria were:

- 1. acute myocardial infarction, transient ischemic attack, acute cerebrovascular accident less than 3 months before the start of the study;
- 2. patients who were scheduled to undergo myocardial revascularization or heart transplantation during the observation period;
- 3. congenital and acquired defects, as well as heart tumors, LV aneurysm, if scheduled for surgery during the observation period;
- 4. active inflammatory and autoimmune diseases of the myocardium;
- 5. thyrotoxicosis at the time of inclusion in the study;
- 6. anemic syndrome: blood hemoglobin level less than 90 g/l;
- 7. diseases limiting life expectancy to less than 1 year.

Patients underwent investigation according to standard pro forma with some additional research methods appropriate for this study.

The standard research methods included:

- clinical examination (complaints, medical history, physical examination) before CRT and 1 year after CRT;
- general blood test, biochemical blood test (glucose, potassium, sodium, creatinine, urea, total bilirubin and its fractions, total cholesterol, total protein, AST, ALT), general urinalysis before CRT;
- 12-lead ECG before and 1 year after CRT; ECG monitoring during CRT device programming and during the entire observation period;
- echocardiographic studies before and 1 year after CRT to assess LV reverse remodeling;

- stress tests to exclude/confirm coronary artery disease: stress echocardiography, bicycle ergometry or treadmill test, where clinically indicated;
- coronary angiography, where clinically indicated.

The additional research methods included:

- ECG recording in intrinsic rhythm and under BiV pacing, while programming the CRT device within 7 days after implantation.
- Electrocardiographic imaging using an Amycard system (Amycard, EP Solutions SA, Yverdon, Switzerland). Prior to ECG imaging, a maximum of 224 unipolar body surface mapping electrodes were placed on the patient's torso, followed by computed tomography (CT) imaging of the heart and thorax (Somatom Definition 128, Siemens Healthcare, Germany). Subsequently, the electrodes were connected to the model 01C multichannel electrophysiology laboratory system (Amycard) for continuous ECG recordings during the pacing protocol. CT data were imported into Wave program version 2.14 (Amycard software) to reconstruct 3-dimensional geometry of the torso and heart. Finally, epi/endo ventricle models were manually built with marked active poles of RV and LV leads for bi-ventricular pacing simulations.
- MRI (MAGNETOM Trio A Tim 3 T, Siemens AG or INGENIA 1.5 T, Philips) with contrast (Gadovist or Magnevist) before CRT to detect structural damage of the myocardium.
- Tissue Doppler echocardiography to record ventricle mechanical dyssynchrony. Analysis of interventricular dyssynchrony (IVD) and intraventricular dyssynchrony in the LV (LVD) was performed using biomarkers suggested by Yu and co-authors ?. IVD was assessed by the time difference between the start of systolic flows into the aorta and the pulmonary trunk as measured by a pulse-wave Doppler, a value of less than 40 ms was taken as an IVD normal value. LVD was assessed using two biomarkers: dyssynchrony index defined as the temporal difference between the maximal and minimal peak systolic velocities between 12 LV segments (Tsmax–Ts min, 105 ms was taken as threshold normal value), and standard deviation in the peak systolic velocities for 12 LV segments (SD–12, 34 ms was taken as cutoff value). To determine the peak systolic velocities, the technique of colour tissue Doppler ultrasonography was used.

Baseline clinical data for the patient cohort are presented in Table S1.

SUMMARY OF CLINICAL AND SIMULATION DATA IN THE PATIENT COHORT

Table S1. Clinical, imaging, model data and ML scores of CRT response in the patient cohort at baseline and BiV pacing with clinical lead configuration (ref-LP).

Variable		All patients (n	=57)		
	Clinical data				
Gender (male/female)	38/19				
Age, year		63±6			
BMI		28±5			
IHD/DCM		36 (63%)/21(3	37%)		
History of AF		12 (21%)			
-	LBBB	CRT	Δ , %	P *	
FC CHF :	de	ecrease in FC 31	1 (54%)		
Ι	0(0%)	10 (17.5%)*	10	0.002	
II	24 (42%)	31 (54.5%)	7	0.052	
III	33 (58%)	6 (10%)*	-27	0.001	
QRSd, ms	191±24	144±19*	-23±14	0.000	
	Echocardiography data				
EDV, ml	294±92	236±119*	-18±31	0.000	
ESV, ml	217±77	159±101*	-24±36	0.000	
EDD, mm	73±8	66±10*	-10±10	0.000	
ESD, mm	63±9	53±12*	-15±17	0.000	
EF, %	26±6	35±8*	9±8	0.000	
	CT/MRI data				
MTV,ml	359±143				
ScarV, ml	50±39				
ScarV/MTV		0.15 ± 0.11			
Scar-LV distance, mm		32±24			
	Model data				
	LBBB	BiV	$\Delta,$ %	P*	
TAT95, ms	150±26	$100\pm 20*$		0.000	
QRSd, ms	189±24	$144 \pm 20*$	-23±13	0.000	
AT_{RVLV} , ms	69±28	7±7*	-113 ± 44	0.000	
mAT_{STLV}	0.25 ± 0.06		-32±11	0.000	
	Predictive model scores				
ML-score		0.41±0.31			

Mean±SD

P* - LBBB vs CRT or LBBB vs BiV. Comparisons between two dependent groups were made using Wilcoxon's test for quantitative data and McNemar's test for qualitative data.

 Δ - Average change in indicator $\Delta X = X_{CRT} - X_{LBBB} / X_{LBBB}$ or $\Delta X = X_{BiV} - X_{LBBB} / X_{LBBB}$. The Δ is calculated as the absolute difference for normalized values (LV EF, mAT_{STLV}), and for FC. BMI – body mass index; IHD – ischemic heart disease; DCM – dilated cardiomyopathy; AF – atrial

BMI – body mass index; IHD – ischemic heart disease; DCM – dilated cardiomyopathy; AF – atrial Fibrilation; FC CHF – functional class of congestive heart failure; MTV – myocardial tissue volume; ScarV – scar/fibrosis volume; Scar-LV distance – distance between LV lead and scar/fibrosis area; TAT95 – 95% of total ventricular activation time; QRSd - maximal duration of QRS complex on 12 leads; AT_{RVLV} - difference of total LV and RV activation time; mAT_{STLV} - difference between mean activation time of LV free wall and septum; ML-score - ML score of CRT response defined as more than 10% LV EF improvement.

Table S2. Clinical, imaging, model data and ML-scores of CRT response in responder and nonresponder subgroups. CRT response is defined as more than 10% improvement in the LV EF under BiV pacing with clinical (referent) lead position (ref-LP) in a year after CRT device implantation.

	Patient cohort n=57						
Variable	Responders n=23 (40%)			Non-responders n=34 (60%)			
	Clinical data						
Gender (male/female)		15/8			23/11		
Age, year		64±6			63±7		
BMI		27±5		30±5#			
IHD/DCM	14	(61%)/9(49%	6)	22	(65%)/12(35%)	
History of AF		4 (17%)			8 (24%)		
	LBBB	CRT	Δ , %	LBBB	CRT	Δ , %	
FC CHF :		se in FC 17 (ase in FC 15 (4		
Ι	0 (0%)	7 (30%)*	7	0 (0%)	3 (9%)	3	
II	12 (52%)		0	12 (35%)	19 (56%)**	7	
III	11(48%)		-9	22 (65%)	4 (12%)**	-18	
QRSd, ms	192 ± 20	143±14**	-25±11	190±26	145±21**	-22±16	
				ography data			
EDV, ml	301±69	196±68**	-33±22	290 ± 106	263±138##		
ESV, ml	231±59	119±48**	-47±19	207 ± 87	185±118*##	-9±37##	
EDD, mm	74±8	62±10**	-16±10	73±7	69±9 **##	-5±8 ##	
ESD, mm	64±9	48±13**	-26±17	62±9	57±10 **##		
EF, %	23±5	40±6 **	17±5	29±6##	32±7**##	3±5##	
			CT/M	IRI data			
MTV,ml		332±142			377±143		
ScarV, ml		45±39			54±39		
ScarV/MTV		0.14 ± 0.08			0.16±0.13		
Scar-LV distance, mm		39±22			26±24#		
	Model data						
	LBBB	BiV	Δ , %	LBBB	BiV	Δ ,%	
TAT95, ms	151±21	98±14**	-34±12	149±29	102±23**	-30±19	
QRSd, ms	191±20	142±15**	-25 ± 10	188±27	145±23**	-21±15	
AT_{RVLV} , ms	65±25	-5±17**	-115±35	71±29	-2±21**	-112 ± 49	
mAT_{STLV}	0.24 ± 0.07	-0.07±0.1	-31±9	0.26 ± 0.06	-0.06±0.1**	-32±12	
	Predictive model scores						
ML-score		0.64 ± 0.3			0.25±0.22##		

Mean±SD

* - p<0.05, ** - p<0.01 LBBB vs CRT or LBBB vs BiV. Comparisons between two dependent groups were made using Wilcoxon's test for quantitative data and McNemar's test for qualitative data. # - p<0.05, ## - p<0.01 Responders vs Non-responders. Comparison between two independent groups was carried out using the Mann-Whitney test for quantitative data and Pearson's chi-square test for qualitative

data.

 Δ - Average change in indicator $\Delta X = X \text{ CRT} - X \text{ LBBB} / X \text{LBBB}$ or $\Delta X = X \text{BiV} - X \text{ LBBB} / X \text{ LBBB}$. Δ is calculated as the absolute difference for normalized values (EF and mAT_{STLV}) and FC BMI - Body mass index; IHD -Ischemic heart disease; DCM - Dilated cardiomyopathy; AF - Atrial Fibrillation; FC CHF- functional class of congestive heart failure; MTV - myocardial tissue volume; ScarV – scar/fibrosis volume; Scar-LV distance – distance between LV lead and scar/fibrosis area; TAT95 - 95% of total ventricular activation time; QRSd – maximal QRS duration in 12-lead ECG; AT_{RVLV} – difference of total LV and RV activation time; mAT_{STLV} – difference between mean activation time of LV free wall and septum; ML-score – ML score of CRT response defined as more than 10% LV EF improvement.

SCARRING AREA IN THE LEFT VENTRICLE




Figure S1. Distribution of the simulated scar/fibrosis area between 17 segments in AHA LV model based on MRI data in the patient cohort. Left panel shows the number of patients (out of 57 total) with scar/fibrosis area in each segment of 17-segment AHA LV models. Right panel shows a relative volume of damaged myocardium in the segments.

LV PACING SITE LOCATION




Figure S2. Distribution of the LV pacing site locations in the 17–segment AHA model for different pacing designs in the patient cohort. The number of patients (out of 57) with pacing lead located in the segment is indicated.

ML CLASSIFIER OF CRT RESPONSE

Figure S3 shows a list of clinic and simulated features used to develop logistic regression classifier (LR) in the range of their significance for CRT response prediction (right panel). A ROC curve for the final LR classifier based on selected 7 most significant features (see red lines on the right) with ROC AUC of 0.84.




Figure S3. Machine Learning Classifier for CRT response prediction from the hybrid dataset of clinical and model-derived data for 57 patients. **Left panel** shows receiver operating characteristic (ROC) curves for the ML classifier based on the $\Delta EF > 10\%$ criterion of CRT response. Value of the area under the ROC curve (ROC AUC) for the model is shown on the panel. **Right panel** lists clinical and model-derived features in the descending order of importance ranged using a logistic regression feature selection approach for the ML classifier.

A list of features and corresponding logistic regression (LR) weights in the final LR classifier are shown in TableS3. The LR classifier generates an ML-score based on the clinical and simulated features of the patients. Cross-table and characteristics of the LR classifier are shown below.

Table S3. Logistic Regression classifier of CRT response defined as more than 10% improvement in LV EF

Feature	Data type	Non-standardized coefficient of LR	Standardized coefficient of LR
EF, %	Clinical	-15.33	-1.16
AT_{RVLV} LBBB, ms	Simulated	-0.04	-0.98
BMI	Clinical	-0.19	-0.90
Scar-LV distance, mm	Simulated	0.03	0.84
TAT_LBBB/MTV	Simulated	3.96	0.75
EDD, mm	Clinical	0.08	0.70
AT_{RVLV} BiV, ms	Simulated	-0.02	-0.37
Intercept of LR		2.76	-0.51

LR - Logistic Regression

BMI - Body mass index; TAT95 - 95% of total ventricular activation time; MTV - myocardial tissue volume; AT_{RVLV} - difference of total LV and RV activation time; EDD – end diastolic diameter of LV; EF – ejection fraction.

Table S4. LR classifier performance

ROC AUC	=0.84, cut-off $= 0.5$	Clinic Responder	Clinic Non-responde		
LR positi	ve (ML-SCR >0,5)	15	4		
LR negative (ML-SCR <0,5)		8	30		
Accuracy Sensitivity		Specificity	ppv	npv	
77%	65%	88%	75%	78%	

COMPARISON OF SIMULATED FEATURES IN DIFFERENT VENTRICULAR ACTIVATION DESIGNS

Table s5. Comparison of inter-ventricular (AT_{RVLV}) and intra-ventricular (mAT_{STLV}) electrical dyssynchrony indices at baseline LBBB and BiV pacing with different LV lead positions in the total patient cohort and subgroups of responders and non-responders

Simulated			Total Cohort (n=57)		
featur		Value	Increment (BiV – LBBB)	Increment (opt-LP – ref-LP)	
LBBB		69±28			
	ref-LP	7±7*	-72±28		
AT_{RVLV} , ms	ML-LP	$-3\pm20^{*}$	$-62\pm27^{\$}$	10±20	
	LAT-LP	$-2\pm18^{*}$	-71±30 ^{&}	$-1\pm11^{\&}$	
	TAT-LP	$-4\pm17^{*}$	-73±26 ^{&}	-1±13 ^{&}	
	LBBB	0.25 ± 0.06			
	ref-LP	$-0.07\pm0.1^{*}$	-0.32 ± 0.11		
mAT_{STLV}	ML-LP	$0.09 \pm 0.06^{*}$	-0.16±0.08 ^{\$}	0.16±0.11	
	LAT-LP	-0.08±0.1*&	-0.33±0.12 ^{&}	-0.01±0.09 ^{&}	
	TAT-LP	$0\pm0.07^{*\%}$	-0.26±0.11 ^{\$&}	0.06±0.1 ^{&}	
			Responders (n=	23)	
	LBBB	65±25			
AT_{RVLV} , ms	ref-LP	$-5\pm17^{*}_{*^{\circ}}$	-71±29		
AI_{RVLV} , IIIS	ML-LP	$8\pm8^{*\$}$	-58±24 ^{\$}	13±15	
	LAT-LP	$-3\pm16^{*}$	-68±29 ^{&}	$2\pm8^{\&}$	
	TAT-LP	-3±14*	$-69\pm27^{\&}$	2±12	
	LBBB	0.24±0.07			
mAT_{STLV}	ref-LP	$-0.07\pm0.1^{*}$	-0.31±0.09		
<i>mAISTLV</i>	ML-LP	0.1±0.07 ^{*\$}	-0.14±0.09\$	0.17±0.10	
	LAT-LP	-0.06±0.1*&	-0.31±0.10&	0.00±0.05&	
TAT-LP		$0.02 \pm 0.06^{*\$}$	-0.23±0.09 ^{\$}	$0.08 \pm 0.09^{\&}$	
		71.00	Non-responders (1	n=34)	
	LBBB	71±29	72 : 27		
AT_{RVLV} , ms	ref-LP	-2±21*	-73±27		
RV LV, IIIS	ML-LP	6±7*	-65±30\$	8±22	
	LAT-LP	-2±20*	-73±30 ^{&}	0±12	
	TAT-LP	-5±19*	-76±25 ^{\$&}	-3±14	
	LBBB	0.26±0.06	0.00.0.10		
mAT_{STLV}	ref-LP	-0.06±0.1*	-0.32±0.12		
IIII II STLV	ML-LP	0.08±0.05*\$	-0.18±0.07	0.15±0.11	
	LAT-LP	-0.09±0.09*&	-0.35±0.13	-0.03±0.11 ^{&}	
	TAT-LP	-0.02±0.08 ^{*\$} &	-0.28±0.12	0.05±0.11 ^{&}	

Mean±SD

- p<0.05, * - p<0.01 opt-LP vs LBBB. \$ - p<0.05, \$ - p<0.01 opt-LP vs ref-LP . & - p<0.05, & - p<0.01 opt-LP vs ML-LP . Comparison of dependent groups was performed using Friedman's test, followed by a pairwise comparison adjusted for multiple comparisons.

- p<0.05, # - p<0.01 Řesponders vs Non-responders. Comparison between two independent groups was carried out using Mann-Whitney test. AT_{RVLV} - difference of total LV and RV activation time; mAT_{STLV} - difference between mean activation time of LV free wall and septum.

		Total Cohort (n=57)		Responders (n=23)		Non-responders (n=34)	
Simul feat		Value	Increment (opt-LP – ref-LP)	Value	Increment (opt-LP – ref-LP)	Value	Increment (opt-LP – ref-LP)
RV-LV	ref-LP	103±40	0 + 4 1	112±31	1(+24	97±45	2+44
delay,	ML-LP	96±47 147±42 ^{\$&}	-8±41 44±34 ^{&}	96±50 144±34 ^{\$&}	-16±34 32±12 ^{&}	96±46 149±47 ^{\$&}	-2±44
ms	LAT-LP				-		$52\pm 40^{\&}$
	TAT-LP ref-LP	$\frac{80\pm37}{100\pm22}$	-23±40	75 ± 32 101±21	-38±41	84±40 99±24	-13±37#
RV-LV	ML-LP	97 ± 29	-3±33	93 ± 29	-7±24	100 ± 29	1±37
distance, mm	LAT-LP	110±23 ^{\$}	10 ± 27	105±17	4±21	113±26	14 ± 30
111111	TAT-LP	103±18	3±24	96±14	-4±20	$107 \pm 20^{\#}$	8±25
LAT-LV	ref-LP	57±25		54±23		59±27	
distance,	ML-LP	74±30 ^{\$}	17±37	$77 \pm 27^{\$}$	23±30	73±31	13 ± 41
mm	LAT-LP	0±0 ^{\$&}	-57±25 &	0±0 ^{\$&}	-54±23 &	0±0 ^{\$&}	-59±27&
	TAT-LP	62±25	5±33	60±26	6±31	63±25	4±35
Scar-LV	ref-LP	32±24		39±22		26 ± 24 [#]	
distance,	ML-LP	57±21 ^{\$}	26±20	$59\pm20^{\$}$	20±17	56±21 ^{\$}	30±22
mm	LAT-LP	24±27 ^{&}	-8±24 ^{&}	27±27 ^{&}	-12±18 ^{&}	22 ± 27 ^{&}	-4±27 ^{&}
	TAT-LP	19±19 ^{&}	-13±27&	16±18 ^{\$&}	-23±27&	20±20 ^{&}	-6±26 ^{&#</sup></td></tr></tbody></table>}

Table S6. Comparison of model-derived features at different LV pacing lead positions in the total patient cohort and subgroups of responders and non-responders

Mean±SD

-p<0.05, -p<0.01 opt-LP vs ref-LP. & -p<0.05, -p<0.01 opt-LP vs ML-LP. Comparison of dependent groups was performed using Friedman's test, followed by a pairwise comparison adjusted for multiple comparisons.

- p < 0.05, # - p < 0.01 Responders vs Non-responders. Comparison between two independent groups was carried out using Mann-Whitney test.

DISTRIBUTION OF CLINICAL RESPONDERS AND NON-RESPONDERS BETWEEN SUBGROUPS CLASSIFIED AS POSITIVE OR NEGATIVE TO CRT RESPONSE

In Table S7 we show a cross-table of LR classifier predictions of positive (ML-score>0.5) and negative (ML-score <0.5) response to CRT for clinic responders and non-responders. Different colors show true and false positive (red and orange) and true and false negative (black and blue) in the patient cohort as classified from LR fed by simulations for the referent pacing lead positions (ref-LP). In the lower rows we show similar cross-tables for different optimal lead positions with indication of transitions between the subgroups.

The total ratio of patients classified as positive and negative to CRT response for each optimized LV pacing lead position is shown in the right column. It can be that only the ML-score based optimal LV lead position (ML-LP) increases the amount of positive to CRT response as compared to that observed in clinic.

Table S7. Cross-table between clinical responders/ non-responders and positive/negative prediction of CRT response at BiV pacing with different LV pacing lead positions

LP	MI acore	Clinic		
LP	ML-score	Responder	Non-responder	Total
		23 (40%)	34(60%)	
CLD	ML-SCR>0.5 (positive)	15	5	20 (35%)
ref-LP	ML-SCR<0.5 (negative)	8	29	37 (65%)
	ML-SCR>0.5 (positive)	15 + 5 =20	5 + 6 =11	31 (54%)
ML-LP	ML-SCR<0.5 (negative)	8-5=3	29-6 =23	26 (46%)
LATID	ML-SCR>0.5 (positive)	15 - 2 + 2 =15	5-1 +2=6	21 (37%)
LAT-LP	ML-SCR<0.5 (negative)	8-2+2=8	29 - 2+1 =28	36 (63%)
TATID	ML-SCR>0.5 (positive)	15 - 5 +1=11	5-1 +2=6	17 (30%)
TAT-LP	ML-SCR<0.5(negative)	8 -1+ 5 =12	29 - 2+1 =28	40 (70%)

ML-SCR - ML-score **True Positive False Negative by refLP False Positive by refLP True Negative**